Literature DB >> 7909653

Immunity to erythrocytic stages of malarial parasites.

C A Long1, T M Daly, P Kima, I Srivastava.   

Abstract

In those individuals who live in endemic areas, immunity to malaria is slow to develop and stage-specific. The nature and antigenic specificity of this response, which may involve components of both cell-mediated and humoral immunity, is not well understood. Rodent models provide useful systems to explore the spectrum of host responses that may contribute to resolution of erythrocytic-stage infection or possibly to pathogenesis. Moreover, these models allow identification of plasmodial molecules that can induce different types of host responses. Two different mouse model systems, Plasmodium yoelii yoelii and P. chabaudi adami are presented. These have been selected because resolution of infection by P. yoelii yoelii has been shown to require B cell-dependent mechanisms, while control of acute P. chabaudi adami infection can be achieved by T cell-dependent mechanisms. A monoclonal antibody that provides passive protection to P. yoelii challenge infection has been shown to recognize the cysteine-rich, carboxyl-terminal region of the merozoite surface protein-1. This region, obtained in an appropriate configuration from recombinant Escherichia coli, can induce significant protective immune responses in naive mice. In contrast, cell-mediated immune mechanisms make a major contribution to resolution of asexual-stage P. chabaudi adami infection. An empirical approach using continuous flow electrophoresis has identified several low molecular weight plasmodial proteins that can induce partial protective responses in susceptible hosts. These observations are briefly discussed with respect to human malaria.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909653     DOI: 10.4269/ajtmh.1994.50.27

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

1.  Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.

Authors:  C Yang; W E Collins; J S Sullivan; D C Kaslow; L Xiao; A A Lal
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

2.  Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.

Authors:  Asma Abdullah Nurul; Mohd Nor Norazmi
Journal:  Parasitol Res       Date:  2010-11-06       Impact factor: 2.289

3.  Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine.

Authors:  T Scorza; K Grubb; P Smooker; A Rainczuk; D Proll; T W Spithill
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

4.  Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.

Authors:  S Dutta; L A Ware; A Barbosa; C F Ockenhouse; D E Lanar
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

5.  Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.

Authors:  Suraksha Sachdeva; Gul Ahmad; Pawan Malhotra; Paushali Mukherjee; V S Chauhan
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 6.  Malaria vaccines.

Authors:  R Amador; M E Patarroyo
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

7.  Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.

Authors:  E Elsa Herdiana Murhandarwati; Lina Wang; Harini D de Silva; Charles Ma; Magdalena Plebanski; Casilda G Black; Ross L Coppel
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

8.  Secreted antibody is required for immunity to Plasmodium berghei.

Authors:  Julia K Nunes; Michael N Starnbach; Dyann F Wirth
Journal:  Infect Immun       Date:  2008-11-10       Impact factor: 3.441

9.  MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum.

Authors:  Elke S Bergmann-Leitner; Elizabeth H Duncan; Evelina Angov
Journal:  Malar J       Date:  2009-08-03       Impact factor: 2.979

10.  Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Authors:  Elke S Bergmann-Leitner; Elizabeth H Duncan; Ryan M Mease; Evelina Angov
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.